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Editorial on the Research Topic
Burden of Illness in People With Epilepsy: From Population-Based Studies to Precision
Medicine
Epilepsy is a common and chronic neurological disease that is characterized by recurrent seizures
which impose a major burden on patients, their caregivers, and society (1, 2). The aim of this
Research Topic was thus to provide evidence that personalized translational epilepsy research will
benefit patients through targeted experimental (3), clinical and network research (4, 5). There is a
fast growing number of publications that deal with personalized or precision approaches for the
treatment of epilepsy, Figure 1.
People with epilepsy face disease-specific restrictions concerning self-sufficiency, mobility,
career choice, family planning, and other social aspects (6, 7). An analysis of patients with
severe drug-refractory epilepsy showed a seven-fold increase in mortality, along with high costs
and frequent epilepsy-related accidents and injuries (Strzelczyk et al.). The authors used a
German health insurance database to administer a top-down approach, drawing patients from
a representative cohort and matched them to a cohort that was not affected. Comorbidities, like
depression and vascular disorders, were significantly increased in patients with epilepsy (Strzelczyk
et al.). Focusing on epilepsy-related accidents and injuries, Willems et al. used a bottom-up
approach in a cross-sectional study, and it showed that there was a possibility of a reduced quality
of life and increased depression scores in affected patients (Willems et al.). The presented data in
both studies fits well with other recent burden-of-disease studies that showed the costs for hospital
treatment and anticonvulsants as being major cost drivers (8–11) and that persisting seizures were
also associated with a reduced quality of life (12, 13).
While the use of newer anticonvulsants may be associated with increased costs, it also has
the potential to significantly reduce the seizure burden. Brivaracetam is the latest anticonvulsant
that has been approved as an add-on therapy for the treatment of focal-onset seizures (14). A
single-center study from Marburg in Germany (Zahnert et al.) shows promising post-marketing
results in a cohort of mainly drug-refractory patients, while another multi-center study focused on
patients with epileptic encephalopathies (Willems et al.). In both studies, 50% responder rates of 35
to 45% were achieved, which were well in line with other postmarketing results (15–17).
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FIGURE 1 | Number of publications listed in PubMed referring to search terms “Epilepsy” and “personalized” or “precision medicine” (PubMed query on September
13th 2018).
The initial response to anticonvulsants is explored in patients
with newly diagnosed epilepsy, and showed that the initial
6-month response, as well as the number of seizures prior
to treatment and brain-imaging abnormalities, are important
prognostic factors (Xia et al.).
Lifestyle-dependent factors are important, especially in
genetic generalized epilepsies. Until now, it was unclear
as to whether alcohol consumption has an impact on
epilepsy in these patients (18). Even if the risk is generally
increased in patients with epilepsy, patients with genetic
generalized epilepsies have a particularly high risk of
alcohol related-seizures after the consumption of a
large amount of alcohol. This can also be attributed to
accompanying factors, such as altered sleep architecture or
impaired adherence to antiepileptic medication (Hamerle
et al.).
The genetic architecture of common non-lesional focal
epilepsies was evaluated in a study that uses a customized panel
of 21 well-known focal epilepsy genes (Tsai et al.). The study
revealed that only 1.85% (11/593 patients) carried pathogenic or
likely pathogenic variants in these genes, and this indicated that
other yet to be discovered genes play a role as well.
Comorbidities, such as cognitive issues, are often present in
patients with epilepsy (19). Gorny et al. showed that not all scales
that were used to assess global cognitive function, work reliably
in patients with epilepsy.
Structural abnormalities associated with clinical and
neuropsychological characteristics in genetic epilepsies was
evaluated in two studies on juvenile myoclonic epilepsy (JME)
using MRI diffusion tensor imaging (DTI), and in benign
childhood epilepsy, with centrotemporal spikes (BECTS), which
used the graph theory analysis based on the cortical gyrification
index, respectively (Domin et al.; Jiang et al.). In JME, the extent
of microstructural abnormalities within the subcortical networks,
including cortico-cortical, thalamo-frontal, and cortico-spinal
connections, determined the clinical manifestation and subtype
of JME in the individual patient, such as photoparoxysmal
responses or seizures with predominant motor symptoms
(Domin et al.). In contrast, abnormal cortical folding that was
mainly in the central region is presumably the neuroanatomical
basis for BECTS (Jiang et al.). The findings of both studies are
important steps for the establishing of the pathophysiological
concepts found in genetic epilepsies.
A step forward in the care for people with epilepsy could be
through the introduction of technological therapies. Page et al.
pointed out in their perspective article that there has been an
increase in patient-triggered interventions, a finding based on
automated monitoring of indicators and risk factors facilitated
by technological advances. The main goal of such interventions
would be the reduction of epilepsy-related mortality with SUDEP
(Sudden Unexpected Death in Epilepsy) being the main reason
for epilepsy-related deaths (20, 21).
An important point on this road is the development of an
automatic computer-based detection algorithm of seizures. In
their review, Baumgartner et al. described the use of potential
bio signals, such as scalp EEG, ECG, and surface EMG, which
can be combined for an algorithm and implemented into devices.
The daily work of clinicians may be significantly improved
by the use of an automated long-term EEG review. This was
described by Koren et al. as an automatic critical care EEG
pattern detection method that would be helpful in reducing
review times.
This Research Topic presents a compilation of different
studies which increases the visibility of the high burden
associated with epilepsy, along with providing some directions
as to how personalized or precision approaches may help
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to overcome this burden. In the coming years we will see
a dramatic increase in personalized or precision medicine,
Figure 1, that will significantly contribute to the management of
epilepsy.
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